Study details
Enrolling now
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis
Genentech, Inc.
NCT IDNCT06096779ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
30
Study length
about 2.3 years
Ages
18+
Locations
60 sites in AZ, CA, CO +21
What this study is about
Researchers are testing the safety of atezolizumab alone or with bevacizumab as a first treatment for liver cancer that cannot be removed surgically. The trial will last about 854 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Atezolizumab
- 2.Take Bevacizumab
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IVInjection / IV
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
atezolizumab, bevacizumab
Drug routes
injection (Injection), infusion
Endpoints
Primary: Percentage of Participants With Adverse Events (AEs)